Javascript must be enabled to continue!
Abstract 1544: Cell penetrating single domain antibody (sdAb) SBT-100 binds KRAS and inhibits growth of human cancers with KRAS activating mutations
View through CrossRef
Abstract
Background: Despite nearly fourth years of research, scientists have failed to develop a clinically viable therapy against KRAS, one of the deadliest families of cancer-causing proteins. Mutations in KRAS are prevalent amongst the top three most deadly cancer types in the United States: pancreatic (95%), colorectal (45%), and lung (35%). KRAS has been thought to be undruggable due to: 1) its intracellular location and lack of binding pockets for small molecules; 2) the high (pM) affinity of RAS for GTP precludes direct targeting of the nucleotide binding pocket; 3) high intracellular concentrations of GTP (uM) inhibits competition for the nucleotide-binding pocket by small molecules; and 4) possible toxicity. Mutations of KRAS result in it being perpetually turned on to propagate signal down the MAPK pathway. This results in constant production of P-ERK and plays an important role in malignant development. To overcome these challenges, Singh Biotechnology has developed SBT-100 a first in class & best in class novel sdAb that penetrates the cell membrane to bind KRAS to inhibit its GTPase activity.
Methods: Human cancer cell lines were purchased from ATCC. BIAcore affinity studies were conducted by Precision Antibody. KRAS GTPase assay was purchased from Promega. Levels of P-ERK were determined using western blots. In vitro cell growth suppression was tested with MTT assay. Athymic nude mice for xenograft studies were purchased from Envigo.
Results: SBT-100 binds KRAS with KD=10-9 and KRAS(G12D) with KD=10-7 as demonstrated by BIAcore affinity assay. Both SBT-100 and SBT-102 significantly inhibit KRAS GTPase activity in vitro and inhibition is comparable to polyclonal antibody to KRAS. Growth of MDA-MB-231 cells with KRAS(G13D) mutation and PANC-1 cells with KRAS(G12D) mutation are significantly decreased in the MTT assay when incubated with SBT-100. Additionally, same cell lines have significantly decreased P-ERK expression when cultured with SBT-100. Xenograft studies demonstrate significant growth suppression of MDA-MB-231 and PANC-1 when treated with SBT-100 in vivo.
Conclusion: SBT-100, crosses the cell membrane, binds to KRAS intracellularly and its most common mutant with nanomolar affinity, inhibits KRAS GTPase activity, downregulates P-ERK signaling, and suppresses the growth of cancers cells in vitro and in vivo without showing any toxic effects.
Citation Format: Sunanda Singh, Genoveva Murillo, Avani Singh, Samara Singh, Meenakshi Parihar, Anjali Singh, Rajendra Mehta, Ashutosh Parihar. Cell penetrating single domain antibody (sdAb) SBT-100 binds KRAS and inhibits growth of human cancers with KRAS activating mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1544.
American Association for Cancer Research (AACR)
Title: Abstract 1544: Cell penetrating single domain antibody (sdAb) SBT-100 binds KRAS and inhibits growth of human cancers with KRAS activating mutations
Description:
Abstract
Background: Despite nearly fourth years of research, scientists have failed to develop a clinically viable therapy against KRAS, one of the deadliest families of cancer-causing proteins.
Mutations in KRAS are prevalent amongst the top three most deadly cancer types in the United States: pancreatic (95%), colorectal (45%), and lung (35%).
KRAS has been thought to be undruggable due to: 1) its intracellular location and lack of binding pockets for small molecules; 2) the high (pM) affinity of RAS for GTP precludes direct targeting of the nucleotide binding pocket; 3) high intracellular concentrations of GTP (uM) inhibits competition for the nucleotide-binding pocket by small molecules; and 4) possible toxicity.
Mutations of KRAS result in it being perpetually turned on to propagate signal down the MAPK pathway.
This results in constant production of P-ERK and plays an important role in malignant development.
To overcome these challenges, Singh Biotechnology has developed SBT-100 a first in class & best in class novel sdAb that penetrates the cell membrane to bind KRAS to inhibit its GTPase activity.
Methods: Human cancer cell lines were purchased from ATCC.
BIAcore affinity studies were conducted by Precision Antibody.
KRAS GTPase assay was purchased from Promega.
Levels of P-ERK were determined using western blots.
In vitro cell growth suppression was tested with MTT assay.
Athymic nude mice for xenograft studies were purchased from Envigo.
Results: SBT-100 binds KRAS with KD=10-9 and KRAS(G12D) with KD=10-7 as demonstrated by BIAcore affinity assay.
Both SBT-100 and SBT-102 significantly inhibit KRAS GTPase activity in vitro and inhibition is comparable to polyclonal antibody to KRAS.
Growth of MDA-MB-231 cells with KRAS(G13D) mutation and PANC-1 cells with KRAS(G12D) mutation are significantly decreased in the MTT assay when incubated with SBT-100.
Additionally, same cell lines have significantly decreased P-ERK expression when cultured with SBT-100.
Xenograft studies demonstrate significant growth suppression of MDA-MB-231 and PANC-1 when treated with SBT-100 in vivo.
Conclusion: SBT-100, crosses the cell membrane, binds to KRAS intracellularly and its most common mutant with nanomolar affinity, inhibits KRAS GTPase activity, downregulates P-ERK signaling, and suppresses the growth of cancers cells in vitro and in vivo without showing any toxic effects.
Citation Format: Sunanda Singh, Genoveva Murillo, Avani Singh, Samara Singh, Meenakshi Parihar, Anjali Singh, Rajendra Mehta, Ashutosh Parihar.
Cell penetrating single domain antibody (sdAb) SBT-100 binds KRAS and inhibits growth of human cancers with KRAS activating mutations [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA.
Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1544.
Related Results
Single domain antibody (SBT-100) crosses the blood brain barrier (BBB) and inhibits human glioblastoma by selectively targeting KRAS and P-STAT3.
Single domain antibody (SBT-100) crosses the blood brain barrier (BBB) and inhibits human glioblastoma by selectively targeting KRAS and P-STAT3.
e13547 Background: Glioblastoma is difficult to treat malignancy that has a high incidence of KRAS mutations ( > 90%) and hyper-expression of P-STAT3 ( > 90%). Most chemothe...
Effect of KRAS and P-STAT3 inhibition by SBT-100 on gemcitabine and pancreatic cancer growth in vivo.
Effect of KRAS and P-STAT3 inhibition by SBT-100 on gemcitabine and pancreatic cancer growth in vivo.
e15727 Background: Over 90% of pancreatic cancers have KRAS mutations and hyper-expression of P-STAT3 oncoproteins, which if specifically targeted may help treatment of pancreatic...
Abstract 5436: Novel single-domain antibody (sdAb), SBT-100, localizes in the cytoplasm to inhibit IL-6 mediated P-STAT3 nuclear translocation in cancer cells
Abstract 5436: Novel single-domain antibody (sdAb), SBT-100, localizes in the cytoplasm to inhibit IL-6 mediated P-STAT3 nuclear translocation in cancer cells
Abstract
BACKGROUND: Interleukin-6 (IL-6) is a multifunctional cytokine that is involved in immune defense and plays an important role in biologic activities of cell...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Abstract 4699: Single domain antibody (sdAb) localizes in cancer cells to inhibit signal transducer and activator of transcription 3 (STAT3) resulting in therapeutic inhibition of multiple cancers
Abstract 4699: Single domain antibody (sdAb) localizes in cancer cells to inhibit signal transducer and activator of transcription 3 (STAT3) resulting in therapeutic inhibition of multiple cancers
Abstract
STAT3 is involved in the pathogenesis of many malignancies, so we developed an anti-STAT3 VHH (variable region of the heavy chain), SBT-100, that internaliz...
Abstract 2441: The myCAF and ECM landscape in KRAS-mutated cancer: Utilizing liquid biomarkers to track KRAS-induced fibrosis and KRAS inhibitor efficacy
Abstract 2441: The myCAF and ECM landscape in KRAS-mutated cancer: Utilizing liquid biomarkers to track KRAS-induced fibrosis and KRAS inhibitor efficacy
Abstract
Background:
KRAS-driven cancer represents ∼25% of cancers, with high rates in pancreatic cancer (PDAC), colorect...
Abstract 1932: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small molecule therapeutic agent
Abstract 1932: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small molecule therapeutic agent
Abstract
KRAS mutations are highly prevalent across many different cancer types. Recent advancements in KRAS-targeted drugs, such as the FDA-approved KRAS(G12C) inhi...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...

